---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-005577"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T22:11:23.263702+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anika Q2 revenue $38.1M (+24% YoY); raises FY revenue growth outlook to 11-14%

## Summary
- Net income $6.5M ($0.45 diluted EPS) vs net loss $7.7M in Q2 2020.
- Adjusted net income $1.4M ($0.09 diluted EPS); adjusted EBITDA $6.1M.
- Joint Preservation and Restoration revenue up 79% to $11.9M; segment now 31% of total.
- Company raises FY 2021 revenue growth guidance to 11-14% from prior 10-13%.
- First surgical case with WristMotion Total Wrist implant; 510(k) clearance for reverse shoulder system.

## SEC filing metadata
- accession: 0001171843-21-005577
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184321005577/0001171843-21-005577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184321005577/f8k_080521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-005577
- JSON: https://secwatch.observer/filing/0001171843-21-005577.json
- Plain text: https://secwatch.observer/filing/0001171843-21-005577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.